Semaglutide shine polypeptide wanda likitoci suka tsara don kula da nau'in ciwon sukari na 2.FDA ta amince da amfani da Novo Nordisk's Ozempic da Rybelsus azaman allura sau ɗaya kowane mako ko azaman kwamfutar hannu, bi da bi.Allurar semaglutide sau ɗaya-mako-mako tare da alamar sunan Wegovy an ƙara amincewa da kwanan nan azaman maganin asarar nauyi.
Wani sabon bincike da aka gabatar a taron Majalisar Turai kan Kiba na wannan shekara (ECO2023, Dublin, 17-20 May) ya nuna cewa semaglutide na ƙwayar kiba yana da tasiri don asarar nauyi a cikin multicenter, na tsawon shekara 1 na ainihin binciken duniya.Binciken Dr Andres Acosta ne da Dr Wissam Ghusn, Matsakaicin Magunguna don Tsarin Kiba a Mayo Clinic, Rochester, MN, Amurka da abokan aiki.
Semaglutide, glucagon-kamar peptide-1 (GLP-1) agonist mai karɓa, shine mafi kwanan nan da FDA ta amince da maganin kiba.Ya nuna sakamako mai mahimmanci na asarar nauyi a cikin gwaje-gwajen gwaje-gwaje na asibiti da yawa na dogon lokaci da kuma nazarin ɗan gajeren lokaci na ainihi.Duk da haka, an san kadan game da asarar nauyi da sakamakon sigogi na rayuwa a cikin nazarin ainihin duniya na tsakiyar lokaci.A cikin wannan binciken, marubutan sun tantance sakamakon asarar nauyi da ke hade da semaglutide a cikin marasa lafiya da kiba da kiba tare da kuma ba tare da nau'in ciwon sukari na 2 (T2DM) ba a shekara ta 1.
Sun yi nazari na baya-bayan nan, multicentre (Mayo Clinic Asibitocin: Minnesota, Arizona, da Florida) tattara bayanai kan amfani da semaglutide don maganin kiba.Sun haɗa da marasa lafiya tare da ma'auni na jiki (BMI) ≥27 kg / m2 (kiba da duk manyan nau'ikan BMI) waɗanda aka wajabta allurai na mako-mako na semaglutide subcutaneous (magungunan 0.25, 0.5, 1, 1.7, 2, 2.4mg; duk da haka yawancin sun kasance akan. mafi girma kashi 2.4mg).Sun cire marasa lafiya da ke shan wasu magunguna don kiba, waɗanda ke da tarihin tiyatar kiba, masu ciwon daji, da masu ciki.
Maƙasudin ƙarshen farko shine jimlar asarar nauyin jiki (TBWL%) a shekara 1.Matsayin ƙarshen na biyu ya haɗa da rabon marasa lafiya da suka cimma ≥5%, ≥10%, ≥15%, da ≥20% TBWL%, canji a cikin sigogi na rayuwa da na jijiyoyin jini (matsin jini, HbA1c [haemoglobin glycated, ma'aunin sarrafa sukari na jini]. glucose mai azumi da kitse na jini), TBWL% na marasa lafiya tare da kuma ba tare da T2DM ba, da yawan tasirin sakamako a cikin shekarar farko na jiyya.
An haɗa jimlar marasa lafiya 305 a cikin bincike (73% mace, ma'anar shekaru 49, 92% fari, yana nufin BMI 41, 26% tare da T2DM) .Halayen tushe da cikakkun bayanan ziyarar kulawar nauyi an gabatar da su a cikin Teburin 1 cikakken taƙaitaccen bayani.A cikin duka ƙungiyar, ma'anar TBWL% shine 13.4% a shekara ta 1 (ga marasa lafiya 110 waɗanda ke da bayanan nauyi a shekara 1).Marasa lafiya tare da T2DM suna da ƙananan TBWL% na 10.1% don 45 na marasa lafiya na 110 tare da bayanai a cikin shekara 1, idan aka kwatanta da waɗanda ba tare da T2DM na 16.7% na 65 na 110 marasa lafiya tare da bayanai a shekara ta 1.
Yawan marasa lafiya da suka rasa fiye da 5% na nauyin jikinsu shine 82%, fiye da 10% shine 65%, fiye da 15% shine 41%, kuma fiye da 20% shine 21% a shekara 1.Maganin Semaglutide kuma ya rage mahimmancin systolic da diastolic hawan jini ta 6.8/2.5 mmHg;jimlar cholesterol ta 10.2 mg/dL;LDL na 5.1 mg/dL;da triglycerides na 17.6 mg/dL.Rabin marasa lafiya sun sami sakamako masu illa masu alaƙa da amfani da magani (154/305) tare da mafi yawan rahoton kasancewar tashin zuciya (38%) da gudawa (9%) (Hoto 1D).Abubuwan da ke haifar da illa sun kasance mafi sauƙi ba su shafi ingancin rayuwa ba amma a cikin lokuta 16 sun haifar da dakatar da maganin.
Marubutan sun kammala: "Semaglutide yana da alaƙa da asarar nauyi mai yawa da haɓaka sigogi na rayuwa a cikin shekara ta 1 a cikin rukunin yanar gizo na ainihi na duniya, yana nuna tasirin sa a cikin maganin kiba, a cikin marasa lafiya tare da ba tare da T2DM ba."
Ƙungiyar Mayo suna shirya wasu rubuce-rubucen da yawa da suka shafi semaglutide, ciki har da sakamakon nauyi a cikin marasa lafiya da suka sake dawowa bayan aikin tiyata na bariatric;Sakamakon asarar nauyi a cikin marasa lafiya waɗanda ke kan wasu magungunan rigakafin kiba a baya idan aka kwatanta da waɗanda ba su da.
Lokacin aikawa: Satumba-20-2023